Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Sarcoma 1Other 1Breast 1

Conditions

Obesity 1Neoplasm Metastasis 1Gliosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Disease 1Carcinosarcoma 1

Interventions

Paclitaxel 7Specimen Handling 6Radiotherapy 4Magnetic Resonance Spectroscopy 4Biopsy 4pembrolizumab 3Taxes 3Nivolumab 3Carboplatin 3trastuzumab deruxtecan 2olaparib 2ceralasertib 2aflibercept 2X-Rays 2Psychiatric Rehabilitation 2Irinotecan 2Ipilimumab 2Immunoglobulin G 2Ifosfamide 2Gene Expression Profiling 2Fulvestrant 2Filgrastim 2Fentanyl 2Doxorubicin 2Bevacizumab 2trifluridine tipiracil drug combination 1toripalimab 1tinostamustine 1spartalizumab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × TIC10 compound × Sarcoma × Clear all
NCT05542407 2026-01-29

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
58 enrolled
GynecologicOtherSarcoma

Carcinosarcoma, Disease, Neoplasm Metastasis, Obesity, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡